News and insights

Syncona FY20: Martin Murphy discusses the impact of COVID-19

Syncona FY20: Martin Murphy discusses the outlook for Syncona

Danny Bar-Zohar joins Syncona as Partner

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, announces the appointment of Danny Bar-Zohar, M.D., as Syncona Partner, from 17 April 2020. In this role, Danny will leverage his expertise in clinical development, regulatory environments and medical affairs to help Syncona further build and establish its portfolio of life science companies.

COVID-19: Syncona Business Update

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today provides an update on its business following the outbreak of the COVID-19 pandemic.

Lorenz Mayr Appointed as Entrepreneur in Residence

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, announces the appointment of Lorenz Mayr, Ph.D. as Entrepreneur in Residence, from 1 January 2020. In this role, he will have a particular focus on sourcing new Syncona companies, developing and driving portfolio company business plans and strategy.

Found, Build and Fund

Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris describe Syncona’s strategy to Found, Build and Fund global leaders in life science.

Syncona Expands Global Leadership Position In Gene Therapy With Foundation Of New Companies

Syncona further strengthens position in gene therapy; foundation of SwanBio and Orbit Biomedical takes gene therapy group to five companies.